View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
November 4, 2021updated 11 Jul 2022 2:19pm

Infectious disease trials have highest increase of delayed start date since 2016

This year has seen the highest number of infectious disease trials with delayed start dates than at any point in the last five years.

By GlobalData Healthcare

Rescue clinical trials, specifically those that have delayed initial start date, often need rescuing for many reasons, such as resources becoming scarce and the impact of the Covid-19 pandemic. GlobalData’s Pharmaceutical Intelligence Centre has compiled data on rescue trials, noticing a trend in delayed initial trial start dates.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Trials with delayed initial start dates have increased steadily since 2016, with the most being this year with 5,578. Looking by therapy area, oncology had the most clinical trials in that period with 7,753 trials, followed by the central nervous system and infectious diseases to round out the top three. But when looking at percentage increases over the past five years, infectious disease was the highest at 198%, followed by the central nervous system at 123% and musculoskeletal disorders at 106%. Oncology had the fourth highest percentage increase with 98%. Lastly, the number of trials with a delayed start date for infectious disease doubled between 2019 and last year. This may be due to companies focusing on vaccines and therapeutics for Covid-19. A further breakdown can be seen in Figure 1.

As trends show, the number of trials with delayed initial start dates will continue to rise. This may be due to the rising number of Covid-19 cases due to its variants, which will create more obstacles for companies to overcome.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena